Annual Review of Cancer Biology-Series最新文献_第3页

Clonal Hematopoiesis: Confluence of Malignant and Nonmalignant Diseases 克隆造血:恶性和非恶性疾病的融合

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2022-01-18 DOI: 10.1146/annurev-cancerbio-060121-120026

A. E. Lin, P. Rauch, S. Jaiswal, B. Ebert

引用次数: 2

Targeting BET Bromodomains in Cancer 靶向癌症中的β-溴代胺

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2022-01-18 DOI: 10.1146/annurev-cancerbio-070120-103531

P. Trojer

{"title":"Targeting BET Bromodomains in Cancer","authors":"P. Trojer","doi":"10.1146/annurev-cancerbio-070120-103531","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-070120-103531","url":null,"abstract":"Cancer is frequently dependent on aberrant gene expression programs that might be vulnerable to targeting with novel therapeutics. Bromodomain and extraterminal domain (BET) proteins are powerful transcriptional coregulators often found as part of oncogenic transcriptional programs. The bromodomain functionality of BET proteins is highly druggable, and several product candidates are in clinical testing. While initial clinical data created doubt about their benefit for cancer patients, more encouraging data recently reported in myelofibrosis patients may promote additional applications of BET inhibitors in oncology as monotherapy and in combination with other therapeutic agents. Moreover, a growing number of approaches to optimize the therapeutic window by tinkering with the property profiles of BET inhibitors may provide additional clinical opportunities. This review provides an update on the status of ongoing activities to exploit BET bromodomain inhibition as a mechanism for cancer therapy. Expected final online publication date for the Annual Review of Cancer Biology, Volume 6 is April 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"1 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44432573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Single-Cell Epigenomics Reveals Mechanisms of Cancer Progression 单细胞表观基因组学揭示癌症进展机制

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2022-01-10 DOI: 10.1146/annurev-cancerbio-070620-094453

Lindsay M. LaFave, Rachel Savage, Jason D. Buenrostro

{"title":"Single-Cell Epigenomics Reveals Mechanisms of Cancer Progression","authors":"Lindsay M. LaFave, Rachel Savage, Jason D. Buenrostro","doi":"10.1146/annurev-cancerbio-070620-094453","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-070620-094453","url":null,"abstract":"Cancer initiation is driven by the cooperation between genetic and epigenetic aberrations that disrupt gene regulatory programs critical to maintain specialized cellular functions. After initiation, cells acquire additional genetic and epigenetic alterations influenced by tumor-intrinsic and -extrinsic mechanisms, which increase intratumoral heterogeneity, reshape the cell's underlying gene regulatory network, and promote cancer evolution. Furthermore, environmental or therapeutic insults drive the selection of heterogeneous cell states, with implications for cancer initiation, maintenance, and drug resistance. The advancement of single-cell genomics has begun to uncover the full repertoire of chromatin and gene expression states (cell states) that exist within individual tumors. These single-cell analyses suggest that cells diversify in their regulatory states upon transformation by co-opting damage-induced and nonlineage regulatory programs that can lead to epigenomic plasticity. Here, we review these recent studies related to regulatory state changes in cancer progression and highlight the growing single-cell epigenomics toolkit poised to address unresolved questions in the field. Expected final online publication date for the Annual Review of Cancer Biology, Volume 6 is April 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48381031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches 结直肠癌的肠道微生物群:关联、机制和临床方法

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-12-22 DOI: 10.1146/annurev-cancerbio-070120-095211

Cayetano Pleguezuelos-Manzano, Jens Puschhof, H. Clevers

{"title":"Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches","authors":"Cayetano Pleguezuelos-Manzano, Jens Puschhof, H. Clevers","doi":"10.1146/annurev-cancerbio-070120-095211","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-070120-095211","url":null,"abstract":"Colorectal cancer (CRC) is associated with the presence of particular gut microbes, as observed in many metagenomic studies to date. However, in most cases, it remains difficult to disentangle their active contribution to CRC from just a bystander role. This review focuses on the mechanisms described to date by which the CRC-associated microbiota could contribute to CRC. Bacteria like pks+ Escherichia coli, Fusobacterium nucleatum, or enterotoxigenic Bacteroides fragilis have been shown to induce mutagenesis, alter host epithelial signaling pathways, or reshape the tumor immune landscape in several experimental systems. The mechanistic roles of other bacteria, as well as newly identified fungi and viruses that are enriched in CRC, are only starting to be elucidated. Additionally, novel systems like organoids and organs-on-a-chip are emerging as powerful tools to study the direct effect of gut microbiota on healthy or tumor intestinal epithelium. Thus, the expanding knowledge of tumor-microbiota interactions holds promise for improved diagnosis and treatment of CRC. Expected final online publication date for the Annual Review of Cancer Biology, Volume 6 is April 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"1 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43488384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Tracing and Targeting the Origins of Childhood Cancer 追踪和定位儿童癌症的起源

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-12-21 DOI: 10.1146/annurev-cancerbio-070620-091632

Tim H. H. Coorens, S. Behjati

引用次数: 1

Targeting KRAS G12C with Covalent Inhibitors 用共价抑制剂靶向KRAS G12C

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-12-21 DOI: 10.1146/annurev-cancerbio-041621-012549

J. Ostrem, K. Shokat

引用次数: 11

The Metabolic Relationship Between Viral Infection and Cancer 病毒感染与癌症之间的代谢关系

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-12-15 DOI: 10.1146/annurev-cancerbio-070120-090423

P. Mullen, H. Christofk

引用次数: 4

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy 双特异性T细胞结合免疫疗法靶向实体瘤

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-12-15 DOI: 10.1146/annurev-cancerbio-070620-104325

T. Arvedson, J. Bailis, C. Britten, M. Klinger, D. Nagorsen, A. Coxon, J. Egen, F. Martin

{"title":"Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy","authors":"T. Arvedson, J. Bailis, C. Britten, M. Klinger, D. Nagorsen, A. Coxon, J. Egen, F. Martin","doi":"10.1146/annurev-cancerbio-070620-104325","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-070620-104325","url":null,"abstract":"T cell engagers (TCEs) are targeted immunotherapies that have emerged as a promising treatment to redirect effector T cells for tumor cell killing. The strong therapeutic value of TCEs, established by the approval of blinatumomab for the treatment of B cell precursor acute lymphoblastic leukemia, has expanded to include other hematologic malignancies, as well as some solid tumors. Successful clinical development of TCEs in solid tumors has proven challenging, as it requires additional considerations such as the selectivity of target expression, tumor accessibility, and the impact of the immunosuppressive tumor microenvironment. In this review, we provide a brief history of blinatumomab, summarize learnings from TCEs in hematologic malignancies, and highlight results from recent TCE trials in solid tumors. Additionally, we examine approaches to improve the efficacy and safety of TCEs in solid tumors, including therapeutic combinations to increase the depth and durability of response. Expected final online publication date for the Annual Review of Cancer Biology, Volume 6 is April 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44592807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Telomeres and Cancer: Resolving the Paradox. 端粒和癌症:解决矛盾。

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-03-01 DOI: 10.1146/annurev-cancerbio-050420-023410

Joe Nassour, Tobias T Schmidt, Jan Karlseder

{"title":"Telomeres and Cancer: Resolving the Paradox.","authors":"Joe Nassour, Tobias T Schmidt, Jan Karlseder","doi":"10.1146/annurev-cancerbio-050420-023410","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-050420-023410","url":null,"abstract":"Decades of study on cell cycle regulation have provided great insight into human cellular life span barriers, as well as their dysregulation during tumorigenesis. Telomeres, the extremities of linear chromosomes, perform an essential role in implementing these proliferative boundaries and preventing the propagation of potentially cancerous cells. The tumor-suppressive function of telomeres relies on their ability to initiate DNA damage signaling pathways and downstream cellular events, ranging from cell cycle perturbation to inflammation and cell death. While the tumor-suppressor role of telomeres is undoubtable, recent advances have pointed to telomeres as a major source of many of the genomic aberrations found in both early- and late-stage cancers, including the most recently discovered mutational phenomenon of chromothripsis. Telomere shortening appears as a double-edged sword that can function in opposing directions in carcinogenesis. This review focuses on the current knowledge of the dual role of telomeres in cancer and suggests a new perspective to reconcile the paradox of telomeres and their implications in cancer etiology.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"5 1","pages":"59-77"},"PeriodicalIF":7.7,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39424366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. 原发肿瘤标本体外分析评价肿瘤治疗方法。

IF 7.7 2区医学

Annual Review of Cancer Biology-Series Pub Date : 2021-03-01 Epub Date: 2020-12-08 DOI: 10.1146/annurev-cancerbio-043020-125955

Cristina E Tognon, Rosalie C Sears, Gordon B Mills, Joe W Gray, Jeffrey W Tyner

{"title":"Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.","authors":"Cristina E Tognon, Rosalie C Sears, Gordon B Mills, Joe W Gray, Jeffrey W Tyner","doi":"10.1146/annurev-cancerbio-043020-125955","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-043020-125955","url":null,"abstract":"The use of ex vivo drug sensitivity testing to predict drug activity in individual patients has been actively explored for almost 50 years without delivering a generally useful predictive capability. However, extended failure should not be an indicator of futility. This is especially true in cancer research where ultimate success is often preceded by less successful attempts. For example, both immune- and genetic-based targeted therapies for cancer underwent numerous failed attempts before biological understanding, improved targets, and optimized drug development matured to facilitate an arsenal of transformational drugs. Similarly, the concept of directly assessing drug sensitivity of primary tumor biopsies-and the use of this information to help direct therapeutic approaches-has a long history with a definitive learning curve. In this review, we will survey the history of ex vivo testing as well as the current state of the art for this field. We will present an update on methodologies and approaches, describe the use of these technologies to test cutting-edge drug classes, and describe an increasingly nuanced understanding of tumor types and models for which this strategy is most likely to succeed. We will consider the relative strengths and weaknesses of predicting drug activity across the broad biological context of cancer patients and tumor types. This will include an analysis of the potential for ex vivo drug sensitivity testing to accurately predict drug activity within each of the biological hallmarks of cancer pathogenesis.","PeriodicalId":54233,"journal":{"name":"Annual Review of Cancer Biology-Series","volume":"5 ","pages":"39-57"},"PeriodicalIF":7.7,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1146/annurev-cancerbio-043020-125955","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39157933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9